Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach